Cepheid Gets Emergency Use Authorization for H1N1 Flu Assay | GenomeWeb

NEW YORK (GenomeWeb News) – Cepheid today said that the US Food and Drug Administration has granted an Emergency Use Authorization for the firm's Xpert Flu A Panel test.

The test runs on the firm's GeneXpert System and can identify the 2009 H1N1 influenza virus in less than one hour, said Cepheid. In addition, Cepheid said that it is the first test for the virus granted an EUA for CLIA moderate complexity labs, which means it can be performed in hospital near-patient settings.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.